In addition, the antibody enhanced ADCP by the anti-EGFR antibody cetuximab in vitro, thereby providing further evidence that LILRB1 blockade may enhance the therapeutic efficacy of tumor targeting antibodies by enhancing their ADCP function. The gene discussed is EGFR; the disease is neoplasm.